株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:ヒトパピローマウイルス(HPV)予防ワクチン - 日本における医薬品の予測と市場分析

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 307131
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:ヒトパピローマウイルス(HPV)予防ワクチン - 日本における医薬品の予測と市場分析 PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022
出版日: 2014年03月31日 ページ情報: 英文 86 Pages
概要

ヒトパピローマウイルス(HPV)に対する最初の予防接種ワクチンは、2006年に使用されるようになりました。世界のHPVワクチン市場は今では確立されていますが、従来の目標母集団である若年女子に対するワクチン接種率は依然として低調です。当初、HPVワクチンは子宮頸癌の予防ワクチンとして開発され、上市されました。近年では、その他の癌に対するHPVの役割が次第に認められるようになり、一部の国では定期的なワクチン接種勧奨に男性も含めるなど、幅広い層にワクチン接種が行われるようになってきています。

当レポートでは、日本におけるHPV予防ワクチン市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状

第4章 ワクチン接種勧奨と接種率

  • 日本
    • 接種勧奨と政策
    • 予防接種率
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル
    • Gardasil
    • Cervarix

第6章 アンメットニーズと機会

  • 概要
  • 複数のHPV型に対する予防
  • ワクチン接種率
  • ワクチンの安全性に対する認識
  • HPVワクチンの認識
  • HPVワクチンの価格
  • 特定層で流行しているHPV型の接種率
  • ワクチン接種の順守率
  • HPV感染に対する終生免疫は獲得できず
  • 子宮頸癌検査に対する継続的なニーズ

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望なワクチン
  • 初期開発段階の革新的なHPVワクチン

第8章 市場の見通し

  • 日本
    • 予測
    • 主なイベント
    • 促進要因・障壁

第9章 付録

図表

目次
Product Code: GDHC232CFR

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

GlobalData expects the HPV vaccines market in Japan to diminish over the short term, as the decision of Japan's MHLW to remove its active recommendations for HPV vaccination will severely affect vaccine uptake in the country. Ongoing decisions on the status of HPV vaccination will impact upon HPV vaccine sales in Japan over the forecast period. Even in the case of recommendations for HPV vaccination being reinstated, it is likely that their suspension will have a long-term negative impact on HPV vaccine uptake in the country.

Scope

  • Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Prophylactic Human Papillomavirus Vaccines disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the Japan

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Japan
    • 4.1.1. Vaccination Recommendations and Policies
    • 4.1.2. Vaccination Coverage
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles
    • 5.3.1. Gardasil
    • 5.3.2. Cervarix

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Protection against Multiple HPV Types
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Vaccine Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Perception of Vaccine Safety
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Awareness of HPV Vaccination
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Affordability of HPV Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Coverage of HPV Types Prevalent in Certain Populations
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Vaccine Compliance Rates
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity
  • 6.9. Lifelong Protection from HPV Infection Not Established
    • 6.9.1. Unmet Need
    • 6.9.2. Gap Analysis
    • 6.9.3. Opportunity
  • 6.10. Ongoing Need for Cervical Cancer Screening
    • 6.10.1. Unmet Need
    • 6.10.2. Gap Analysis
    • 6.10.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Clinical Development
    • 7.2.1. Xiamen Innovax (Bivalent Vaccine)
  • 7.3. Innovative HPV Vaccines in Early Development
    • 7.3.1. Low-Cost HPV Vaccines
    • 7.3.2. Universal HPV Vaccines

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccine Approval versus Routine Schedule Inclusion
    • 9.4.3. Vaccines Included
    • 9.4.4. Vaccine Launch Dates and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Author(s)
    • 9.6.1. Author(s)
    • 9.6.2. Therapy Area Director
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Histological Progression Towards Cervical Cancer
  • Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
  • Table 3: Marketed Vaccines for HPV, 2014
  • Table 4: Product Profile - Gardasil
  • Table 5: Phase III Efficacy Trials - Gardasil
  • Table 6: Safety Profile - Gardasil
  • Table 7: Gardasil SWOT Analysis, 2014
  • Table 8: Product Profile - Cervarix
  • Table 9: Phase III Efficacy Trials - Cervarix
  • Table 10: Safety Profile - Cervarix
  • Table 11: Cervarix SWOT Analysis, 2014
  • Table 12: Overall Unmet Needs - Current and Future Level of Attainment
  • Table 13: HPV Vaccines - Phase Pipeline, 2014
  • Table 14: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014
  • Table 15: Sales Forecasts ($) for HPV Vaccines in Japan, 2012-2022
  • Table 16: Key Events Impacting Sales for HPV Vaccines in Japan, 2012-2022
  • Table 17: Japan HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 18: Key Launch Dates
  • Table 19: Key Patent Expiries
  • Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Historical and Projected HPV Vaccination Coverage (%) in Japan among 16-Year-Old Females, 2012-2022
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
  • Figure 3: Sales for HPV Vaccines in Japan by Vaccine Class, 2012-2022
Back to Top